Loading organizations...
LifeRock Ventures operates as a specialized investment firm, strategically funding pioneering companies within the therapeutic innovation sector. The firm targets advancements in gene and cell therapies, precision medicines, diagnostics, medical devices, and digital health technologies. Its investment strategy supports ventures developing groundbreaking healthcare solutions, aiming to accelerate novel medical applications.
Established as a dedicated venture capital entity, LifeRock Ventures directs resources toward emerging companies addressing critical challenges in life sciences and health technology. While specific founding details remain unpublicized, the firm’s inception clearly aims to foster innovation where scientific breakthroughs meet unmet medical needs. This underscores its commitment to advanced healthcare solutions.
The firm’s portfolio encompasses early-stage companies developing diverse health-focused products and services. LifeRock Ventures provides essential funding and guidance, enabling these enterprises to develop and scale their offerings. Its vision is to meaningfully advance healthcare by backing ventures poised to redefine treatment paradigms and enhance global patient outcomes.
LifeRock Ventures has 1 tracked investment across 1 company. The latest tracked deal is $47.0M Series B in Cerevance in April 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2024 | Cerevance | $47.0M Series B | Bioluminescence Ventures, Campbell Murray, Double Point Ventures | ARCH Venture Partners, David Schenkein, Issi Rozen, GV, LUX Capital, Morgenthaler Ventures, SV Health Investors, Bill Gates, Gates Frontier, Lightstone Ventures, MQB Partners |